AlphaQuest LLC Acquires 26,748 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

AlphaQuest LLC lifted its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMABFree Report) by 6,911.6% during the fourth quarter, HoldingsChannel reports. The firm owned 27,135 shares of the company’s stock after purchasing an additional 26,748 shares during the quarter. AlphaQuest LLC’s holdings in Y-mAbs Therapeutics were worth $212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in YMAB. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter worth $44,000. Intech Investment Management LLC bought a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at about $133,000. SG Americas Securities LLC raised its stake in Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock valued at $139,000 after acquiring an additional 4,163 shares during the period. Principal Financial Group Inc. raised its stake in Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after acquiring an additional 1,903 shares during the period. Finally, Empire Financial Management Company LLC bought a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at about $210,000. 70.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.50% of the stock is owned by company insiders.

Y-mAbs Therapeutics Trading Down 1.3 %

YMAB stock opened at $4.67 on Monday. The company’s 50 day moving average is $5.97 and its 200 day moving average is $10.10. The stock has a market cap of $211.17 million, a price-to-earnings ratio of -8.65 and a beta of 0.65. Y-mAbs Therapeutics, Inc. has a 1-year low of $4.25 and a 1-year high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the company posted ($0.02) earnings per share. As a group, sell-side analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on YMAB. Bank of America lowered their price objective on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock. Morgan Stanley decreased their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. Finally, Oppenheimer began coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.30.

Get Our Latest Stock Report on YMAB

Y-mAbs Therapeutics Company Profile

(Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

See Also

Want to see what other hedge funds are holding YMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Y-mAbs Therapeutics, Inc. (NASDAQ:YMABFree Report).

Institutional Ownership by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.